Literature DB >> 25594217

Rifampin use and safety in hospitalized infants.

Christopher J Arnold1, Jessica Ericson1, Jordan Kohman1, Kaitlyn L Corey1, Morgan Oh1, Janet Onabanjo1, Christoph P Hornik1, Reese H Clark2, Daniel K Benjamin1, P Brian Smith1, Vivian H Chu1.   

Abstract

OBJECTIVE: This study aims to examine the use and safety of rifampin in the hospitalized infants. STUDY
DESIGN: Observational study of clinical and laboratory adverse events among infants exposed to rifampin from 348 neonatal intensive care units managed by the Pediatrix Medical Group between 1997 and 2012. RESULT: Overall, 2,500 infants received 4,279 courses of rifampin; mean gestational age was 27 weeks (5th, 95th percentile; 23, 36) and mean birth weight was 1,125 g (515; 2,830). Thrombocytopenia (121/1,000 infant days) and conjugated hyperbilirubinemia (25/1,000 infant days) were the most common laboratory adverse events. The most common clinical adverse events were medical necrotizing enterocolitis (64/2,500 infants, 3%) and seizure (60/2,500 infants, 2%).
CONCLUSION: The overall incidence of adverse events among infants receiving rifampin appears low; however, additional studies to further evaluate safety and dosing of rifampin in this population are needed. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25594217      PMCID: PMC4433596          DOI: 10.1055/s-0034-1543955

Source DB:  PubMed          Journal:  Am J Perinatol        ISSN: 0735-1631            Impact factor:   3.079


  23 in total

Review 1.  Rifampin.

Authors:  Ban Alsayyed
Journal:  Pediatr Rev       Date:  2004-06

2.  Acute renal failure in neonatal sepsis.

Authors:  N B Mathur; Himanshu S Agarwal; Arti Maria
Journal:  Indian J Pediatr       Date:  2006-06       Impact factor: 1.967

Review 3.  Hydrocephalus shunt infections.

Authors:  R Bayston
Journal:  J Antimicrob Chemother       Date:  1994-08       Impact factor: 5.790

4.  Cerebrospinal fluid shunt infections. A review of 35 infections in 32 patients.

Authors:  K R Forward; H D Fewer; H G Stiver
Journal:  J Neurosurg       Date:  1983-09       Impact factor: 5.115

5.  Community-acquired Staphylococcus aureus infections in term and near-term previously healthy neonates.

Authors:  Regine M Fortunov; Kristina G Hulten; Wendy A Hammerman; Edward O Mason; Sheldon L Kaplan
Journal:  Pediatrics       Date:  2006-09       Impact factor: 7.124

6.  Acute renal failure in the neonatal period.

Authors:  Pinar Isik Agras; Aylin Tarcan; Esra Baskin; Nurcan Cengiz; Berkan Gürakan; Umit Saatci
Journal:  Ren Fail       Date:  2004-05       Impact factor: 2.606

7.  Vancomycin and rifampin therapy for Staphylococcus epidermidis meningitis associated with CSF shunts: report of three cases.

Authors:  M E Gombert; S H Landesman; M L Corrado; S C Stein; E T Melvin; M Cummings
Journal:  J Neurosurg       Date:  1981-10       Impact factor: 5.115

8.  Guideline for the evaluation of cholestatic jaundice in infants: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition.

Authors:  Virginia Moyer; Deborah K Freese; Peter F Whitington; Alan D Olson; Fred Brewer; Richard B Colletti; Melvin B Heyman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2004-08       Impact factor: 2.839

Review 9.  Acute renal failure in neonates: incidence, etiology and outcome.

Authors:  F B Stapleton; D P Jones; R S Green
Journal:  Pediatr Nephrol       Date:  1987-07       Impact factor: 3.714

10.  Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia.

Authors:  T Q Tan; E O Mason; C N Ou; S L Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

View more
  3 in total

1.  Impact of Drug Treatment at Neonatal Ages on Variability of Drug Metabolism and Drug-drug Interactions in Adult Life.

Authors:  Stephanie Piekos; Chad Pope; Austin Ferrara; Xiao-Bo Zhong
Journal:  Curr Pharmacol Rep       Date:  2017-01-03

2.  Myelosuppression Rates with Administration of Nafcillin with and without Rifampin in Pediatric Patients.

Authors:  Jolly Kuriakose; Michelle Kaplansky; Caroline M Sierra
Journal:  Pediatr Rep       Date:  2022-06-08

Review 3.  Anti-Wolbachia therapy for onchocerciasis & lymphatic filariasis: Current perspectives.

Authors:  Wan Aliaa Wan Sulaiman; Joseph Kamtchum-Tatuene; Mohd Hazmi Mohamed; Vasudevan Ramachandran; Siew Mooi Ching; Sazlyna Mohd Sazlly Lim; Hasnur Zaman Hashim; Liyana Najwa Inche Mat; Fan Kee Hoo; Hamidon Basri
Journal:  Indian J Med Res       Date:  2019-06       Impact factor: 2.375

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.